• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

VirTrial Acquires Virtual Care Management Platform SnapMD

Share:

December 31, 2019

Highlights on this story:
  • VirTrial acquires SnapMD, a Los Angeles, CA-based full-service enterprise telehealth technology innovator, and solutions provider.
  • The acquisition supports VirTrial’s goal of making hybrid decentralized clinical trials seamless for sponsors, sites, and patients.
  • Financial details of the acquisition were not disclosed.

VirTrial Acquires Virtual Care Management Platform SnapMD
by Fred Pennic 12/16/2019 0 Comments

VirTrial Acquires Virtual Care Management Platform SnapMD

– VirTrial acquires SnapMD, a Los Angeles, CA-based full-service enterprise telehealth technology innovator, and solutions provider.

– The acquisition supports VirTrial’s goal of making hybrid decentralized clinical trials seamless for sponsors, sites, and patients.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

– Financial details of the acquisition were not disclosed.

VirTrial, a portfolio company of Kinderhook Industries, LLC, announced today the acquisition of SnapMD, an LA-based provider of telemedicine tools and services that improve patient engagement. The acquisition bolsters VirTrial’s capabilities with access to SnapMD’s telemedicine platform and technical expertise. In addition, the relationship enables the integration of additional features and capabilities into VirTrial’s Virtual Care Management (VCM) platform to further establish VirTrial as the dominant global decentralized clinical trial (DCT) solution in the market.

SnapMD Virtual Care Management Platform Overview

Founded in 2013, SnapMD’s Virtual Care Management (VCM) telehealth software is a robust digital health system that places the tools of telemedicine in the hands of providers to deliver virtual, high-quality and coordinated care. As a cohesive and complete suite of services in the cloud, the technology enables providers to launch and manage virtual care that can be scaled across a health enterprise and the care continuum. The white-label VCM platform is configured to support multiple hospital and health system service lines with unique operational requirements, and with architecture that can be integrated to work seamlessly with existing and future systems.

SnapMD Acquisition Will Make Hybrid Decentralized Clinical Trials Seamless

The acquisition supports VirTrial’s goal of making hybrid decentralized clinical trials seamless for sponsors, sites, and patients. VirTrial’s platform combines video, text, and email allowing pharmaceutical companies and CROs to create patient-centric Decentralized Clinical Trials (DCTs) by replacing some study visits with virtual visits. The vision is for 25-50% of visits to be conducted virtually creating a hybrid model. This model is ideally suited for Phase III/Phase IV trials where patient compliance can be assessed from any location.

The VirTrial platform works with any device (Apple, Android, tablet and/or computer) and can be used by any site. Continuing that focus on flexibility and ease of use, new enhancements available via SnapMD technology will improve functionality and further simplify user experience. The company will operate as a subsidiary of VirTrial and will continue to provide its market-leading telemedicine solution across the healthcare space. Financial terms of the acquisition were not disclosed.

“Our acquisition of SnapMD enables us to better implement our vision of making clinical trials easier for everyone involved from sponsors to sites and patients. By offering a simplified, straight-forward user experience and the ability for sponsors to include multiple countries with extensive features, VirTrial continues to set the bar in decentralized clinical trial platforms,” said Mark Hanley, CEO of VirTrial.

Source: HIT Consultant

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Allen Technologies and Strategic Healthcare Connections Announce Partnership To Drive Better Health OutcomesAllen Technologies and Strategic Healthcare Connections Announce Partnership To Drive Better Health Outcomes
  • Mass General Brigham, Better Therapeutics Partner on Real-world Data StudyMass General Brigham, Better Therapeutics Partner on Real-world Data Study
  • AmWell IPO and Google Deal – Five Key Takeaways to KnowAmWell IPO and Google Deal – Five Key Takeaways to Know
  • Masimo Rad-G Pulse Oximeter Gets FDA ClearanceMasimo Rad-G Pulse Oximeter Gets FDA Clearance
  • Erich Mauff Acquires Super Voting Shares of Jushi Holdings Inc.Erich Mauff Acquires Super Voting Shares of Jushi Holdings Inc.
  • Blue Sprig Pediatrics Announces Acquisition Of Aptitude Habilitation ServicesBlue Sprig Pediatrics Announces Acquisition Of Aptitude Habilitation Services
  • How Software Solutions Can Help ASCs Maximize the Revenue Cycle in 2020How Software Solutions Can Help ASCs Maximize the Revenue Cycle in 2020
  • Report: Digital Solutions in MA Plans Will be a Minimum Requirement Going ForwardReport: Digital Solutions in MA Plans Will be a Minimum Requirement Going Forward

Trending This Week

  • Pharmaceutical Compliance Software Market 2022 to Showing Impressive Growth By | [no. of Pages: 118] Industry Trends, Share, Size, Top Key Players Analysis and Forecast Research, Shares and Strategies | By Proficient Market Insights
  • Biosimilars Market: Rise in Number of Cancer Patients to Boost Market
  • Biotechnology and Pharmaceutical Services Outsourcing Market Size 2022 Analysis Report By Competitive Vendors in Top Regions and Countries, Production Types, Applications, Growth, Current Trends and Forecast to 2026
  • The Global Wearable Injectors Market Size is Expected to Reach $12.9 Billion By 2028, Rising at a Market Growth of 9.2% CAGR During the Forecast Period
  • Treprostinil Drugs Market – Insights on how Players Have Cemented Their Positions with Disruptive Technologies, Key Players are United Therapeutics, Novartis, and Teva Pharmaceutical Industries Ltd
  • Protect Pharmaceutical Corporation has Acquired Top Notch Software Development Company

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications